Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

A new study suggests belly fat could increase the ... Weight loss drugs such as Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) could be crucial treatment options for patients looking to keep ...

Eli Lilly says a new starting dose regimen for ... and other anti-amyloid drugs and can be life-threatening. In the new study, there was also a larger 67% reduction in ARIA-E among patients ...

Meanwhile, a study ... ahead, Eli Lilly sees revenue growth accelerating to 50% year over year in Q4, powered by increased production capacity and the launch of Mounjaro in new international ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

In a phase 2 study, treatment with the oral GLP-1 drug reduced patients' weight by 14.7% after just 36 weeks. In addition to diabetes and weight loss treatments, Eli Lilly is a big player in the ...

Today's Research Daily features new research reports on 16 major ... Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney ...

A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.